3D5S image
Deposition Date 2008-05-16
Release Date 2008-09-16
Last Version Date 2024-10-30
Entry Detail
PDB ID:
3D5S
Title:
Crystal Structure of Efb-C (R131A) / C3d Complex
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Free:
0.21
R-Value Work:
0.20
Space Group:
P 41
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Complement C3
Gene (Uniprot):C3
Mutations:C1010A
Chain IDs:A, C (auth: B)
Chain Length:297
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Fibrinogen-binding protein
Gene (Uniprot):fib
Mutations:R131A
Chain IDs:B (auth: C), D
Chain Length:65
Number of Molecules:2
Biological Source:Staphylococcus aureus subsp. aureus str. Newman
Primary Citation
Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d.
Protein Sci. 17 1894 1906 (2008)
PMID: 18687868 DOI: 10.1110/ps.036624.108

Abstact

The C3-inhibitory domain of Staphylococcus aureus extracellular fibrinogen-binding protein (Efb-C) defines a novel three-helix bundle motif that regulates complement activation. Previous crystallographic studies of Efb-C bound to its cognate subdomain of human C3 (C3d) identified Arg-131 and Asn-138 of Efb-C as key residues for its activity. In order to characterize more completely the physical and chemical driving forces behind this important interaction, we employed in this study a combination of structural, biophysical, and computational methods to analyze the interaction of C3d with Efb-C and the single-point mutants R131A and N138A. Our results show that while these mutations do not drastically affect the structure of the Efb-C/C3d recognition complex, they have significant adverse effects on both the thermodynamic and kinetic profiles of the resulting complexes. We also characterized other key interactions along the Efb-C/C3d binding interface and found an intricate network of salt bridges and hydrogen bonds that anchor Efb-C to C3d, resulting in its potent complement inhibitory properties.

Legend

Protein

Chemical

Disease

Primary Citation of related structures